Atopic Dermatitis Clinical Trials

• Male or female patients, ≥ 12 years of age on the day of signing the informed consent form and weighing ≥ 40 kg prior to randomization at Baseline

• Chronic atopic dermatitis (AD) defined as onset of AD signs and symptoms

• ≥ 12 months prior to Screening as determined by the Investigator through patient interview and/or review of medical history at the Screening Visit

• Patients must meet the following AD severity criteria:

• IGA score ≥ 3 (scale of 0 to 4) at Screening and Baseline

• ≥ 10.0% of BSA involvement at Screening and Baseline

• EASI ≥ 16.0 at Screening and Baseline

• Are candidates for systemic therapy and have history, documented by a physician and/or the Investigator, of inadequate response to existing topical medications within 6 months preceding Screening, or history of intolerance to a topical therapy

• Provide written, informed consent to participate in the study and follow the study procedures, including compliance with the use of highly effective contraceptives